Developing Bifunctional Beta-lactamase Molecules with Built-in Target-recognizing Module for Prodrug Therapy: Identification of Enterobacter Cloacae P99 Cephalosporinase Loops Suitable for Randomization and Phage-display Selection

Overview

Journal J Mol Recognit

Specialty Molecular Biology

Date 2009 May 14

PMID 19437416

Citations 3

Authors

Girja S Shukla

David N Krag

Affiliations

Soon will be listed here.

Abstract

This study was focused on developing catalytically active beta-lactamase enzyme molecules that have target-recognizing sites built within their scaffold. Using phage-display approach, nine libraries were constructed by inserting the randomized linear or cysteine-constrained heptapeptides in the five different loops on the outer surface of P99 beta-lactamase molecule. The pIII signal peptide of Sec-pathway was employed for a periplasmic translocation of the beta-lactamase fusion protein, which we found more efficient than the DsbA signal peptide of SRP-pathway. The randomized heptapeptide loops replaced native amino acids between positions (34)Y-(37)K, (238)M-(246)A, (275)N-(280)A, (305)A-(311)S, or (329)I-(334)I of the P99 beta-lactamase molecules for generating the loop-1 to -5 libraries, respectively. The diversity of each loop library was judged by counting the primary and beta-lactamase-active clones. The linear peptide inserts in the loop-2 library showed the maximum number of the beta-lactamase-active clones, followed by the loop-5, loop-3, and loop-4. The insertion of the cysteine-constrained loops exhibited a dramatic loss of the enzyme-active beta-lactamase clones. The complexity of the loop-2 linear library, as determined by the frequency and diversity of amino acid distributions in the randomized region, appears consistent with the standards of other types of phage display library systems. The selection of the loop-2 linear library on streptavidin protein as a test target identified several beta-lactamase clones that specifically bound to streptavidin. In conclusion, this study identified the suitability of the loop-2 of P99 beta-lactamase for constructing a phage-display library of the beta-lactamase enzyme-active molecules that can be selected against a target. This is an enabling step in our long-term goal of developing bifunctional beta-lactamase molecules against cancer-specific targets for enzyme prodrug therapy of cancer.

Citing Articles

Cancer cell-specific internalizing ligands from phage displayed beta-lactamase-peptide fusion libraries.

Shukla G, Krag D Protein Eng Des Sel. 2010; 23(6):431-40.

PMID: 20219829 PMC: 2865360. DOI: 10.1093/protein/gzq013.

Phage-displayed combinatorial peptide libraries in fusion to beta-lactamase as reporter for an accelerated clone screening: Potential uses of selected enzyme-linked affinity reagents in downstream applications.

Shukla G, Krag D Comb Chem High Throughput Screen. 2010; 13(1):75-87.

PMID: 20214576 PMC: 2864580. DOI: 10.2174/138620710790218258.

Novel beta-lactamase-random peptide fusion libraries for phage display selection of cancer cell-targeting agents suitable for enzyme prodrug therapy.

Shukla G, Krag D J Drug Target. 2009; 18(2):115-24.

PMID: 19751096 PMC: 2877152. DOI: 10.3109/10611860903244181.

References

Singh Y, Palombo M, Sinko P . Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem. 2008; 15(18):1802-26. PMC: 2802226. DOI: 10.2174/092986708785132997. View

Rooseboom M, Commandeur J, Vermeulen N . Enzyme-catalyzed activation of anticancer prodrugs. Pharmacol Rev. 2004; 56(1):53-102. DOI: 10.1124/pr.56.1.3. View

Cortez-Retamozo V, Backmann N, Senter P, Wernery U, De Baetselier P, Muyldermans S . Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. 2004; 64(8):2853-7. DOI: 10.1158/0008-5472.can-03-3935. View

Vrudhula V, Svensson H, Kennedy K, Senter P, Wallace P . Antitumor activities of a cephalosporin prodrug in combination with monoclonal antibody-beta-lactamase conjugates. Bioconjug Chem. 1993; 4(5):334-40. DOI: 10.1021/bc00023a005. View

Siemers N, Kerr D, Yarnold S, STEBBINS M, Vrudhula V, Hellstrom I . Construction, expression, and activities of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation. Bioconjug Chem. 1997; 8(4):510-9. DOI: 10.1021/bc9700751. View

Vrudhula V, Kerr D, Siemers N, Dubowchik G, Senter P . Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein. Bioorg Med Chem Lett. 2003; 13(3):539-42. DOI: 10.1016/s0960-894x(02)00935-6. View

Jacoby G, Munoz-Price L . The new beta-lactamases. N Engl J Med. 2005; 352(4):380-91. DOI: 10.1056/NEJMra041359. View

Lobkovsky E, Billings E, Moews P, Rahil J, Pratt R, Knox J . Crystallographic structure of a phosphonate derivative of the Enterobacter cloacae P99 cephalosporinase: mechanistic interpretation of a beta-lactamase transition-state analog. Biochemistry. 1994; 33(22):6762-72. DOI: 10.1021/bi00188a004. View

Svensson H, Vrudhula V, Emswiler J, MacMaster J, Cosand W, Senter P . In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Cancer Res. 1995; 55(11):2357-65. View

10.

Michael N, Chester K, Melton R, Robson L, Nicholas W, Boden J . In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein. Immunotechnology. 1996; 2(1):47-57. DOI: 10.1016/1380-2933(96)00033-4. View

11.

Rapoza M, Webster R . The filamentous bacteriophage assembly proteins require the bacterial SecA protein for correct localization to the membrane. J Bacteriol. 1993; 175(6):1856-9. PMC: 203996. DOI: 10.1128/jb.175.6.1856-1859.1993. View

12.

Cwirla S, Peters E, Barrett R, Dower W . Peptides on phage: a vast library of peptides for identifying ligands. Proc Natl Acad Sci U S A. 1990; 87(16):6378-82. PMC: 54537. DOI: 10.1073/pnas.87.16.6378. View

13.

Bagshawe K . Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther. 2006; 6(10):1421-31. DOI: 10.1586/14737140.6.10.1421. View

14.

Seelig B, Szostak J . Selection and evolution of enzymes from a partially randomized non-catalytic scaffold. Nature. 2007; 448(7155):828-31. PMC: 4476047. DOI: 10.1038/nature06032. View

15.

Tanaka T, Ito T, Furuta M, Eguchi C, Toda H, Wakabayashi-Takai E . In situ phage screening. A method for identification of subnanogram tissue components in situ. J Biol Chem. 2002; 277(33):30382-7. DOI: 10.1074/jbc.M203547200. View

16.

Hosse R, Rothe A, Power B . A new generation of protein display scaffolds for molecular recognition. Protein Sci. 2005; 15(1):14-27. PMC: 2242358. DOI: 10.1110/ps.051817606. View

17.

Wilson D, Finlay B . Phage display: applications, innovations, and issues in phage and host biology. Can J Microbiol. 1998; 44(4):313-29. View

18.

Bhatia J, Sharma S, Chester K, Pedley R, BODEN R, Read D . Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein. Int J Cancer. 2000; 85(4):571-7. View

19.

Legendre D, Soumillion P, Fastrez J . Engineering a regulatable enzyme for homogeneous immunoassays. Nat Biotechnol. 1999; 17(1):67-72. DOI: 10.1038/5243. View

20.

Kuhn D, Coates C, Daniel K, Chen D, Bhuiyan M, Kazi A . Beta-lactams and their potential use as novel anticancer chemotherapeutics drugs. Front Biosci. 2004; 9:2605-17. DOI: 10.2741/1420. View